Novel transcript, antisense to NWD2 (ENSG00000293926)

ENSG00000293926 describes a non-coding RNA (novel transcript, antisense to NWD2) that is transcribed in the antisense direction relative to the NWD2 gene locus. Such transcripts are categorized as natural antisense transcripts (NATs), which are widespread in mammalian genomes and can regulate the expression of overlapping or neighboring genes through several mechanisms, including: - Transcriptional interference: where overlapping transcriptional units can inhibit each other's production, - RNA masking: in which duplex formation with the sense transcript can regulate splicing, transport, translation, or stability, - Chromatin remodeling and epigenetic modification: NATs can recruit proteins to modify chromatin structure, thereby influencing gene expression[1][2][3]. NATs generally do not encode proteins and are not considered classical therapeutic targets like receptors, enzymes, or transporters. There is currently no evidence that this specific antisense transcript is a validated therapeutic target or associated with drug interactions, disease, or biomarker use. Its function, if any, remains largely uncharacterized, and its role is likely to be regulatory at the RNA level rather than as a traditional drug target. If you seek a classic therapeutic target (such as a receptor, transporter, enzyme, or similar druggable protein), this entry is not suitable since it represents an uncharacterized non-coding transcript without evidence of direct disease involvement or druggability[4].

Other names

novel antisense transcript to NWD2

Not applicable for drugs; for biology: transcriptional interference, RNA masking, dsRNA-dependent mechanisms, epigenetic regulation[1][2][3]